Clinical Trial Update: Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Famitinib for recurrent and/or metastatic nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Famitinib (Famitinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED